Apr 12, 2018 - Tigenix Sa (OTC:TGXSF): FY net loss of €74.8MRevenue of €0.9M (-96.6% Y/Y)Press Release
Apr 05, 2018 - The biotech sector is fertile ground for tremendously profitable stocks, but many of the names in the sector are also quite risky and volatile.Since the dispersion in returns is so wide in biotech, pi
Mar 23, 2018 - TiGenix (TIG +0.8%) and planned acquirer Takeda Pharmaceutical Company (OTCPK:TKPHF)(OTCPK:TKPYY) announce that the European Commission has approved Alofisel (darvadstrocel), previously known as Cx601
Mar 14, 2018 - Healios to get rights to new indications in Japan and China.Deal sets up commencement of FDA approved global stroke trial.Immunosupression a common link Among stem cell efficacy.
Feb 08, 2018 - Proprietary products utilized in >275 clinical applications, including 45 new applications in 2017.Gilead/Kite, Iovance Biotherapeutics, bluebird bio, TiGenix, TissueGene, Adaptimmune and many more co
Feb 08, 2018 - Fantastic multi-grant supported pipeline with 3 Phase III trials underway, one reporting in 2018. Internal manufacturing is under-appreciated by the market and a huge asset for the company. Data suppo
Jan 31, 2018 - Cash runway until mid September.Share issuance needed to bridge crucial phase III results in Q3.Minimal share issuance shows a sign of confidence in upcoming catalyst.
Jan 16, 2018 -
TiGenix - American Depositary Shares (NASDAQ: TIG) is up over 80 percent since the start of the year, sending the stock above BTIG's price target.
Jan 12, 2018 - TIG call was good timing, nothing more, but now investors may be looking for additional options.There are 3 other stem cell companies which may provide strong cases for investment.Phase III trials are
Jan 12, 2018 - Takeda launches a friendly offer on TiGenix.The offer significantly undervalues the potential of its main drug candidate.Rejecting the offer and waiting for a better one seems to be the best option.